Patent intelligence · US
US 12005069
Bortezomib compositions
Bortezomib compositions
Patent details — US 12005069
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 11, 2024
- Expiration
- Jun 6, 2044
- Applicant
- MAIA PHARMACEUTICALS, INC.
- Claims
- 7
- CPC classes
- A61K, A61K31/198, A61K31/4439, A61K31/573
Quick answer
US 12005069 (Bortezomib compositions) is held by MAIA PHARMACEUTICALS, INC.. Status: granted. Granted Jun 11, 2024. Expires Jun 6, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- MAIA PHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 7
- CPC classes
- A61K, A61K31/198, A61K31/4439, A61K31/573, A61K31/69, A61K45/06
More from MAIA PHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 11992514
Ready-to-use bivalirudin compositions
granted -
US 11918622
Ready-to-use bivalirudin compositions
granted -
US 11903993
Ready-to-use bivalirudin compositions
granted -
US 11752164
Bortezomib compositions
granted -
US 11737983
Storage stable sincalide formulations
granted -
US 11679119
Bortezomib compositions
granted -
US 11672813
Bortezomib compositions
granted
Related coverage
GSK’s Blenrep returns to the US market after FDA approves resubmission
The FDA has approved GSK’s Blenrep in combination with bortezomib and dexamethasone, clearing the drug’s return to the US market. The move ends a withdrawal that followed a failed confirmatory study and resets the catalyst timeline for investors and BD teams.
GSK Blenrep wins FDA approval in relapsed multiple myeloma
GSK’s Blenrep has returned to the U.S. market after the FDA approved it in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. The catalyst matters for BD teams and investors because it reverses a prior withdrawal and resets the drug’s U.S. label and commercial outlook.
Frequently asked questions
What is US patent 12005069?
US 12005069 (Bortezomib compositions) is held by MAIA PHARMACEUTICALS, INC.. Status: granted. Granted Jun 11, 2024. Expires Jun 6, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12005069?
MAIA PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.
When does US 12005069 expire?
Our index shows an expiration date of Jun 6, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.